Effects of Standardized Boswellia Carterii Extract on Irritable Bowel Syndrome Patients
Key facts
- Who runs it
- Mansoura University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2/3
- People taking part
- 60 people enrolled
- Started
- 1 Jan 2025
- Ended
- 30 Jan 2026
- Type of study
- Interventional
- Treatments tested
- Boswellia carterii Extract
- Educationntal program for IBS patie
- Record updated
- 8 May 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Adults diagnosed with irritable bowel syndrome (IBS) according to Rome III and Rome IV criteria Recurrent abdominal pain occurring at least once weekly during the preceding three months Presence of changes in stool frequency, stool form, or defecation associated with abdominal pain Participants reporting bloating as the primary symptom
Who cannot take part
- Adherence to special diets (low-fat, lactose-free, or gluten-free diets) within the past six months Food allergies such as soy, nuts, or seafood allergies Insulin-dependent diabetes mellitus Celiac disease Inflammatory bowel disease History of major gastrointestinal surgery, including colonic surgery or cholecystectomy Bloody diarrhea, hematochezia, or melena Recent antibiotic use Presence of alarming gastrointestinal symptoms Severe renal disease Severe hepatic disease Pregnancy Breastfeeding
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Irritable bowel syndrome (IBS) is a common condition that affects the stomach and intestines. It can cause abdominal pain, bloating, diarrhea, constipation, and changes in bowel habits, which may reduce a person's quality of life. Many people with IBS do not achieve complete symptom relief with standard treatments.
Read full original descriptionShow less
The purpose of this study is to evaluate whether a standardized Boswellia extract, combined with structured patient education, can help improve IBS symptoms and quality of life. Boswellia is a herbal extract that may help reduce inflammation and digestive discomfort.
In this study, 60 adults aged 18-39 years with moderate IBS were enrolled at Mansoura University Hospitals, Egypt. Participants received 500 mg of standardized Boswellia extract twice daily for 30 days and attended educational sessions about IBS self-management, including symptom control and healthy lifestyle practices.
Researchers evaluated abdominal pain, bloating, bowel habits, other gastrointestinal symptoms, and quality of life at the start of the study, after one week, and after one month to determine whether the intervention improved IBS symptoms and daily functioning.
The group in the trial
- Participants received 500 mg standardized Boswellia extract (≥65% boswellic acids) twice dailyTreatment being tested
Phytochemical standardization of the Boswellia carterii oleogum resin extract was conducted at the FAB-Lab (Faculty of Pharmacy, Mansoura University) to ensure batch-to-batch consistency and defined bioactive content. The extract was standardized to contain ≥65% total boswellic acids, based on previously established analytical and isolation methodologies developed in our laboratory. These procedures include chromatographic separation and characterization of immunomodulatory triterpenoids(7), as well as validation of leukotriene-inhibitory activity and bioactive compound profiling, as described in earlier pharmacological and clinical investigations of Boswellia preparations(8). The standardization approach has been consistently applied in prior experimental and clinical studies evaluating anti-inflammatory, immunomodulatory, antiviral, and osteoarthritis-related therapeutic effects of Boswellia-derived compounds, thereby ensuring reproducibility, phytochemical integrity, and biological
Treatment: Boswellia carterii Extract and Educationntal program for IBS patie
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Quasi-experimental Study Evaluating a Standardized Boswellia Carterii Extract Combined With Structured Patient Education in IBS
- Record updated
- 8 May 2026